Fintel reports that on April 2, 2025, BTIG initiated coverage of NRx Pharmaceuticals (NasdaqCM:NRXP) with a Buy ...

BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

Fintel reports that on March 31, 2025, BTIG upgraded their outlook for Progyny (NasdaqGS:PGNY) from Neutral to Buy. Analyst ...

Meeting to be held in Dallas on April 8 hosted by BTIG.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

Jonathan Krinsky, chief market technician at BTIG, sees more slumps for the S&P 500 Index (SPX) forming “W-shape” recoveries, instead of “V-shape” recoveries. The S&P 500 Index (SPX) is ...

BTIG Research assumed coverage on shares of Super Group (NYSE:SGHC – Free Report) in a research note published on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 ...

Shares of CrowdStrike (NASDAQ: CRWD) surged higher on Monday. The move up comes as the S&P 500 and Nasdaq Composite had ...

Ovid Therapeutics (NASDAQ:OVID – Get Free Report) had its price objective cut by BTIG Research from $5.00 to $4.00 in a ...

Investing.com -- BTIG downgraded Ally Financial (NYSE:ALLY) Inc to Sell from Neutral with a $30 target saying a challenging macroeconomic condition and increased competition in the auto lending ...

But Jonathan Krinsky, technical strategist at BTIG, has some potentially good news for equity bulls. Short-term technical signals suggest the S&P 500 and Nasdaq 100 are oversold, he says, and the ...

BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...